Patents by Inventor David A. Giljohann

David A. Giljohann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Delivery of oligonucleotide-functionalized nanoparticles
    Patent number: 11633503
    Abstract: The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: April 25, 2023
    Assignee: Northwestern University
    Inventors: Chad A. Mirkin, Amy S. Paller, David A. Giljohann
  • Nanoconjugates able to cross the blood-brain barrier
    Patent number: 10398784
    Abstract: Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: September 3, 2019
    Assignee: NORTHWESTERN UNIVERITY
    Inventors: Chad A. Mirkin, Caroline H. Ko, David A. Giljohann, Janina Luciano, Samuel A. Jensen, Alexander Stegh
  • Polyvalent RNA-nanoparticle compositions
    Patent number: 10391116
    Abstract: The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: August 27, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos, Andrew E. Prigodich, Pinal C. Patel
  • Nucleic acid functionalized nanoparticles for therapeutic applications
    Patent number: 10370661
    Abstract: Materials and methods for regulating gene expression using nanoparticles functionalized with antisense oligonucleotides are provided.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: August 6, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Nathaniel L. Rosi, C. Shad Thaxton, David A. Giljohann
  • Nucleic acid functionalized nanoparticles for therapeutic applications
    Patent number: 10370656
    Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: August 6, 2019
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos
  • Delivery of Oligonucleotide-Functionalized Nanoparticles
    Publication number: 20190030185
    Abstract: The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.
    Type: Application
    Filed: October 15, 2018
    Publication date: January 31, 2019
    Inventors: Chad A. Mirkin, Amy S. Paller, David A. Giljohann
  • Delivery of oligonucleotide functionalized nanoparticles
    Patent number: 10098958
    Abstract: The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: October 16, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Amy S. Paller, David A. Giljohann
  • SPHERICAL NUCLEIC ACID (SNA)-MEDIATED DELIVERY OF LIPID-COMPLEXES TO CELLS
    Publication number: 20180214376
    Abstract: The invention relates to spherical nucleic acids for the delivery of lipid nucleic acid particles. The lipid nucleic acid particles containing one or more therapeutic agents are coated with an oligonucleotide shell to enhance delivery.
    Type: Application
    Filed: July 14, 2016
    Publication date: August 2, 2018
    Applicant: Exicure, Inc.
    Inventor: David A. GILJOHANN
  • NANOCONJUGATES ABLE TO CROSS THE BLOOD-BRAIN BARRIER
    Publication number: 20180193484
    Abstract: Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 12, 2018
    Inventors: Chad A. Mirkin, Caroline H. Ko, David A. Giljohann, Janina Luciano, Samuel A. Jensen, Alexander Stegh
  • Nucleic Acid Functionalized Nanoparticles for Therapeutic Applications
    Publication number: 20180187189
    Abstract: Materials and methods for regulating gene expression using nanoparticles functionalized with antisense oligonucleotides are provided.
    Type: Application
    Filed: July 19, 2017
    Publication date: July 5, 2018
    Inventors: Chad A. Mirkin, Nathaniel L. Rosi, C. Shad Thaxton, David A. Giljohann
  • TEMPLATED NANOCONJUGATES
    Publication number: 20180117175
    Abstract: The present disclosure is directed to compositions comprising templated nanoconjugates and methods of their use.
    Type: Application
    Filed: August 30, 2017
    Publication date: May 3, 2018
    Inventors: Chad A. Mirkin, David A. Giljohann, Weston L. Daniel, Joshua I. Cutler, Ke Zhang, Dan Zheng
  • Polyvalent RNA-Nanoparticle Compositions
    Publication number: 20180085390
    Abstract: The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.
    Type: Application
    Filed: November 10, 2017
    Publication date: March 29, 2018
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos, Andrew E. Prigodich, Pinal C. Patel
  • Particles for detecting intracellular targets
    Patent number: 9890427
    Abstract: Methods describing the use of nanoparticles modified with binding moieties are provided.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: February 13, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Dwight S. Seferos, David A. Giljohann
  • Nanoconjugates able to cross the blood-brain barrier
    Patent number: 9889209
    Abstract: The present disclosure is directed to nanoconjugates that cross the blood-brain barrier and methods of their therapeutic use.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 13, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Caroline H. Ko, Alexander Stegh, David A. Giljohann, Janina Luciano, Samuel A. Jensen
  • Polyvalent RNA-nanoparticle compositions
    Patent number: 9844562
    Abstract: The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: December 19, 2017
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos, Andrew E. Prigodich, Pinal C. Patel
  • Templated nanoconjugates
    Patent number: 9757475
    Abstract: The present disclosure is directed to compositions comprising templated nanoconjugates and methods of their use.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: September 12, 2017
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, David A. Giljohann, Weston L. Daniel, Joshua I. Cutler, Ke Zhang, Dan Zheng
  • SPHERICAL NUCLEIC ACIDS (SNA) FLARE BASED FLUORESCENCE IN SITU HYBRIDIZATION
    Publication number: 20170240960
    Abstract: The invention relates to a method of performing in situ hybridization such as fluorescence in situ hybridization (FISH) using liposomal spherical nucleic acids (L-SNAs) nanoparticles labeled with dye molecules. The nanoparticles contain one or more nucleic acids that recognize a target of interest in a sample.
    Type: Application
    Filed: February 21, 2017
    Publication date: August 24, 2017
    Applicant: AuraSense, LLC
    Inventors: David A. Giljohann, Richard Kang, Pinal Patel
  • Nucleic acid functionalized nonoparticles for therapeutic applications
    Patent number: 9719089
    Abstract: Materials and methods for regulating gene expression using nanoparticles functionalized with antisense oligonucleotides are provided.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: August 1, 2017
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Chad A. Mirkin, Nathaniel L. Rosi, C. Shad Thaxton, David A. Giljohann
  • NUCLEIC ACID FUNTIONALIZED NANOPARTICLES FOR THERAPEUTIC APPLICATIONS
    Publication number: 20170137809
    Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.
    Type: Application
    Filed: October 18, 2016
    Publication date: May 18, 2017
    Inventors: Chad A. Mirkin, David A. Giljohann, Dwight S. Seferos, Pinal C. Patel
  • OLIGONUCLEOTIDE SPECIFIC UPTAKE OF NANOCONJUGATES
    Publication number: 20170044544
    Abstract: Disclosed are nanoparticles functionalized with an oligonucleotide and a domain, wherein the domain increases cellular uptake of the nanoparticles. The domain is a sequence of nucleobases or phosphate groups, such as a poly thymidine (polyT) sequence or a phosphate polymer (C3 residue) and may be located 5? to the oligonucleotide 3? to the oligonucleotide, within, or colinear with the oligonucleotide. Usage of the nanoparticles including modulating gene regulation is contemplated.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Chad A. Mirkin, David A. Giljohann